Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN) is expected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Geron to post earnings of ($0.03) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

Geron Stock Down 2.1%

NASDAQ:GERN opened at $1.88 on Monday. The stock has a 50-day simple moving average of $1.44 and a 200 day simple moving average of $1.34. Geron has a 52-week low of $1.04 and a 52-week high of $2.66. The company has a market cap of $1.20 billion, a PE ratio of -15.67 and a beta of 0.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.87 and a current ratio of 5.96.

Institutional Investors Weigh In On Geron

A number of institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 24,410 shares during the period. Amundi acquired a new stake in shares of Geron in the fourth quarter valued at approximately $38,000. Franklin Resources Inc. bought a new position in shares of Geron during the 3rd quarter worth approximately $45,000. Cibc World Markets Corp acquired a new position in shares of Geron during the 4th quarter worth approximately $48,000. Finally, Atom Investors LP raised its stake in Geron by 137.0% in the 4th quarter. Atom Investors LP now owns 37,341 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 21,588 shares during the period. 73.71% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GERN. Needham & Company LLC lowered their price objective on shares of Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. TD Cowen reiterated a “buy” rating on shares of Geron in a research note on Thursday, January 29th. HC Wainwright reissued a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. UBS Group restated a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Geron currently has an average rating of “Hold” and an average target price of $2.75.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.